Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2007 1
2008 1
2009 1
2011 1
2012 4
2013 1
2014 1
2015 1
2016 1
2018 2
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

16 results
Results by year
Filters applied: . Clear all
Page 1
Cell Origins of High-Grade Serous Ovarian Cancer.
Kim J, Park EY, Kim O, Schilder JM, Coffey DM, Cho CH, Bast RC Jr. Kim J, et al. Among authors: schilder jm. Cancers (Basel). 2018 Nov 12;10(11):433. doi: 10.3390/cancers10110433. Cancers (Basel). 2018. PMID: 30424539 Free PMC article. Review.
Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
Tew WP, Sill MW, Walker JL, Secord AA, Bonebrake AJ, Schilder JM, Stuckey A, Rice L, Tewari KS, Aghajanian CA. Tew WP, et al. Among authors: schilder jm. Gynecol Oncol. 2018 Nov;151(2):257-263. doi: 10.1016/j.ygyno.2018.08.027. Epub 2018 Aug 31. Gynecol Oncol. 2018. PMID: 30177462 Free PMC article. Clinical Trial.
Stage Ia-IIa cancer of the cervix.
Schilder JM, Stehman FB. Schilder JM, et al. Cancer J. 2003 Sep-Oct;9(5):395-403. doi: 10.1097/00130404-200309000-00010. Cancer J. 2003. PMID: 14690315 Review.
Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Monk BJ, Sill MW, Walker JL, Darus CJ, Sutton G, Tewari KS, Martin LP, Schilder JM, Coleman RL, Balkissoon J, Aghajanian C. Monk BJ, et al. Among authors: schilder jm. J Clin Oncol. 2016 Jul 1;34(19):2279-86. doi: 10.1200/JCO.2015.65.8153. Epub 2016 May 23. J Clin Oncol. 2016. PMID: 27217446 Free PMC article. Clinical Trial.
The Morphology Index: predictive value of malignancy among clinicians at various levels of training.
Barnsfather K, Fitzpatrick CB, Wilson J, Linn CL, Brizendine E, Schilder JM. Barnsfather K, et al. Among authors: schilder jm. Gynecol Oncol. 2012 Oct;127(1):94-7. doi: 10.1016/j.ygyno.2012.06.043. Epub 2012 Jul 6. Gynecol Oncol. 2012. PMID: 22776722
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
Bender D, Sill MW, Lankes HA, Reyes HD, Darus CJ, Delmore JE, Rotmensch J, Gray HJ, Mannel RS, Schilder JM, Hunter MI, McCourt CK, Samuelson MI, Leslie KK. Bender D, et al. Among authors: schilder jm. Gynecol Oncol. 2015 Sep;138(3):507-12. doi: 10.1016/j.ygyno.2015.07.018. Epub 2015 Jul 15. Gynecol Oncol. 2015. PMID: 26186911 Free PMC article. Clinical Trial.
A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
Dizon DS, Sill MW, Schilder JM, McGonigle KF, Rahman Z, Miller DS, Mutch DG, Leslie KK. Dizon DS, et al. Among authors: schilder jm. Gynecol Oncol. 2014 Dec;135(3):441-5. doi: 10.1016/j.ygyno.2014.10.001. Epub 2014 Oct 13. Gynecol Oncol. 2014. PMID: 25312396 Free PMC article. Clinical Trial.
Elevated and secreted phospholipase A₂ activities as new potential therapeutic targets in human epithelial ovarian cancer.
Cai Q, Zhao Z, Antalis C, Yan L, Del Priore G, Hamed AH, Stehman FB, Schilder JM, Xu Y. Cai Q, et al. Among authors: schilder jm. FASEB J. 2012 Aug;26(8):3306-20. doi: 10.1096/fj.12-207597. Epub 2012 Jul 5. FASEB J. 2012. PMID: 22767227 Free PMC article.
Identification of the optimal pathway to reach an accurate diagnosis in the absence of an early detection strategy for ovarian cancer.
Hess LM, Stehman FB, Method MW, Weathers TD, Gupta P, Schilder JM. Hess LM, et al. Among authors: schilder jm. Gynecol Oncol. 2012 Dec;127(3):564-8. doi: 10.1016/j.ygyno.2012.08.029. Epub 2012 Aug 30. Gynecol Oncol. 2012. PMID: 22940492
Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Alvarez EA, Brady WE, Walker JL, Rotmensch J, Zhou XC, Kendrick JE, Yamada SD, Schilder JM, Cohn DE, Harrison CR, Moore KN, Aghajanian C. Alvarez EA, et al. Among authors: schilder jm. Gynecol Oncol. 2013 Apr;129(1):22-7. doi: 10.1016/j.ygyno.2012.12.022. Epub 2012 Dec 20. Gynecol Oncol. 2013. PMID: 23262204 Clinical Trial.
16 results
Jump to page
Feedback